Josephine Torrente's practice involves many aspects of pharmaceutical and biological product law, with a particular focus on new drug and biologic approval issues.
Josephine has broad expertise in IND and NDA matters including clinical trial issues, 505(b)(2) NDAs, REMS, user fee issues, advisory committee meetings, orphan drugs, fast track, special protocol assessments, targeted therapy, cell and tissue based therapies, oncology products, and formal dispute resolution.
Prior to joining the firm in 1998, Josephine was in private practice at Dechert Price & Rhoads primarily working on mergers, acquisitions and securities matters. From 1991-1997, Josephine was employed by Wyeth-Ayerst Research as a research scientist to conduct preclinical studies and as a regulatory professional to continue development of, and seek approval for, promising oncologic, immuno-modulating and anti-infective drugs.
Josephine received a Bachelor of Science in Biomedical Engineering from Case Western Reserve University, and a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham. She graduated, summa cum laude, from Temple University School of Law and is admitted to practice law in the District of Columbia.